Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB(TM) SEAD(TM), a non-invasive treatment for abnormal uterine bleeding (AUB)
Modiin, Israel (ots/PRNewswire) - The trial assesses the safety and efficacy of the IUB(TM) SEAD(TM), a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive ...
plus